• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >Immunotherapy options for painful bladder syndrome: what's the potential?
【24h】

Immunotherapy options for painful bladder syndrome: what's the potential?

机译：痛苦膀胱综合征的免疫疗法选择：有什么潜力？

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Painful bladder syndrome/interstitial cystitis (PBS/IC) is an enigmatic disease characterized by lack of evidence-based knowledge and an ongoing scientific debate regarding its definition, pathogenesis, diagnostic and treatment algorithm. An autoimmune theory for PBS/IC etiology has suggested immunotherapy as a potential treatment choice.Areas covered: In this review, the authors report existing and future immunotherapeutic options, potentially valuable to the management of PBS/IC while evidence for the immunological aspect of PBS/IC pathogenesis are also presented. Relevant data reported in human clinical studies but also in experimental studies using animal PBS/IC models have been reviewed.Expert opinion: Promising data has emerged lately regarding use of immunotherapy drugs for PBS/IC treatment. Specifically, human monoclonal antibodies inhibiting nerve growth factor and tumor necrosis factor-a have shown high efficacy in pain control for PBS/IC. Also, many other agents modulating immunopathways linked to PBS symptom etiology and leading to positive treatment effects have been reported lately mainly in experimental animal studies. Immunotherapy could potentially improve disease-related and patient-reported outcome; nevertheless, lack of consensus regarding PBS/IC diagnostic criteria, leading to high heterogeneity of patients enrolled in PBS/IC treatment studies, and low number of well-designed randomized clinical trials are limitations which must be addressed in the future.
机译：介绍：痛苦的膀胱综合征/间质膀胱炎（PBS / IC）是一种神秘的疾病，其特征在于缺乏基于证据的知识和关于其定义，发病机制，诊断和治疗算法的持续科学辩论。对PBS / IC病因的自身免疫理论提出了免疫疗法作为潜在的治疗选择。涵盖：在本综述中，作者报告了现有和未来的免疫治疗选择，可能对PBS免疫方面的证据有价值的PBS / IC。 / IC发病机制也呈现。已经审查了人类临床研究中报告的相关数据，而且在使用动物PBS / IC模型的实验研究中进行了综述.Expert意见：最近出现了关于PBS / IC治疗的免疫疗法药物的有前途的数据。具体而言，抑制神经生长因子和肿瘤坏死因子-A的人单克隆抗体在PBS / IC的疼痛控制中表现出高效率。此外，许多其他药物调节与PBS症状病因相关的免疫病变和导致阳性治疗效果的症状，主要是在实验动物研究中。免疫疗法可能会改善疾病相关和患者报告的结果;然而，关于PBS / IC诊断标准缺乏共识，导致患有PBS / IC治疗研究的患者的高异质性，并且较少设计的良好的随机临床试验是必须在未来解决的限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号